Drug Trial Radar · NCT07785193
A Study of Subcutaneous FL115 Monotherapy in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
29
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Sep 2027
Study completion Sep 2029
Sponsor
- Lead sponsor
- Suzhou Forlong Biotechnology Co., LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Novotech (Australia) Pty Limited
- First posted
- Aug 25, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter, dose-escalation Phase Ib clinical study to evaluate the safety, tolerability, efficacy, PK, and PD of FL115 injection administered subcutaneously as monotherapy in participants with advanced solid tumours. All enrolled participants will receive FL115 by subcutaneous injection. Each treatment cycle comprises 21 days, with administration once every 3 weeks (Q3W). Treatment will continue until initiation of new anti-tumour therapy, progressive disease (PD), unacceptable toxicity, death, withdrawal of informed consent, loss to follow-up, or study termination by the Sponsor, whichever occurs first.
Conditions
- Advanced Solid Tumours
Interventions
FL115Drug
FL115 is a novel long-acting IL-15 agonist designed as a fusion protein with a mutated IL-15 structure (IL-15\[N72D\]/IL-15Rα-sFc).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of TEAEs and SAEsTime frame: TEAEs: From first dose to 30 days after the last dose or initiation of new anti-tumour therapy, whichever occurs first. SAEs: From PICF signing through the TEAE collection period; thereafter, only treatment- or study-related SAEs will be collected.
- MTD and RP2DTime frame: through study completion, an average of 15 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Integrated Clinical Oncology Network Pty Ltd
South Brisbane, Queensland, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.